Document is current
Any future updates will be listed below
-
Authors
Lorito, Nicla https://orcid.org/0000-0003-2354-2622
Subbiani, Angela https://orcid.org/0000-0001-7184-0734
Smiriglia, Alfredo
Bacci, Marina https://orcid.org/0000-0001-8506-2179
Bonechi, Francesca
Tronci, Laura
Romano, Elisabetta https://orcid.org/0009-0002-0252-3780
Corrado, Alessia
Longo, Dario Livio https://orcid.org/0000-0002-6906-9925
Iozzo, Marta https://orcid.org/0000-0003-2533-6646
Ippolito, Luigi https://orcid.org/0000-0001-7927-8555
Comito, Giuseppina
Giannoni, Elisa https://orcid.org/0000-0001-7136-1098
Meattini, Icro
Avgustinova, Alexandra
Chiarugi, Paola https://orcid.org/0000-0001-7655-2969
Bachi, Angela https://orcid.org/0000-0003-4842-6556
Morandi, Andrea https://orcid.org/0000-0002-9222-5332
-
Funding
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (1915)
Fondazione AIRC per la ricerca sul cancro ETS (22941)
Fondazione AIRC per la ricerca sul cancro ETS (8797)
- License Information
-
More Information
Article History
Received: 29 June 2023
Revised: 24 May 2024
Accepted: 31 May 2024
First Online: 26 June 2024
Disclosure and competing interests statement
: IM declares consultant honoraria for Eli Lilly, Novartis, Seagen, Istituto Gentili, Roche, Pfizer, Ipsen, and Pierre Fabre. All the other authors declare no competing interests.
